ADBIOTECH Appoints New CEO Kim Do-hyung After Resignation of Kim Dong-hyun Limited Impact on Shareholder Value but Low Board Attendance Raises Governance Risk
New CEO Kim Do-hyung was appointed on June 19, 2026, following the resignation of former CEO Kim Dong-hyun.
Kim Do-hyung previously served as CEO of KOSDAQ-listed Notus and currently holds the same position at unlisted Onhill.
This change does not involve any capital movement, so there is no share dilution or capital raising effect.
However, all two outside directors and the auditor were absent from the board resolution, raising governance concerns.
[AI Summary]ADBIOTECH's CEO change is limited to management replacement with minimal short-term stock price impact, but low board attendance signals weakness in decision-making transparency.